From Bench to Bedside: Review of Gene and Cell-Based Therapies and the Slow Advancement into Phase 3 Clinical Trials, with a Focus on Aastrom’s Ixmyelocel-T by Ronnda L. Bartel et al.
From Bench to Bedside: Review of Gene and Cell-Based
Therapies and the Slow Advancement into Phase 3 Clinical
Trials, with a Focus on Aastrom’s Ixmyelocel-T
Ronnda L. Bartel & Erin Booth & Caryn Cramer &
Kelly Ledford & Sharon Watling & Frank Zeigler
Published online: 1 March 2013
# The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract There is a large body of preclinical research dem-
onstrating the efficacy of gene and cellular therapy for the
potential treatment of severe (limb-threatening) peripheral
arterial disease (PAD), including evidence for growth and
transcription factors, monocytes, and mesenchymal stem
cells. While preclinical research has advanced into early phase
clinical trials in patients, few late-phase clinical trials have
been conducted. The reasons for the slow progression of these
therapies from bench to bedside are as complicated as the
fields of gene and cellular therapies. The variety of tissue
sources of stem cells (embryonic, adult bone marrow, umbil-
ical cord, placenta, adipose tissue, etc.); autologous versus
allogeneic donation; types of cells (hematopoietic, mesenchy-
mal stromal, progenitor, and mixed populations); confusion
and stigmatism by the public and patients regarding gene,
protein, and stem cell therapy; scaling of manufacturing; and
the changing regulatory environment all contribute to the
small number of late phase (Phase 3) clinical trials and the
lack of Food and Drug Administration (FDA) approvals. This
review article provides an overview of the progression of
research from gene therapy to the cellular therapy field as it
applies to peripheral arterial disease, as well as the position of
Aastrom’s cellular therapy, ixmyelocel-T, within this field.
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Introduction
The exploration of cellular therapies and their application
to various diseases and conditions is not new. Bone
marrow stem cells have been studied since the 1950s.
Accepted treatments are primarily for hematopoietic stem
cells (HSCs) collected from the bone marrow or the
peripheral blood for transplantation and treatment of spe-
cific types of bone marrow cancers (leukemia, lympho-
ma, and myeloma). Since the 1950s and 60s, the
trajectory of cellular research has climbed steadily up-
ward but few cellular therapies are Food and Drug Ad-
ministration (FDA) approved [1]. The reasons for the
slow progression from bench to bedside are as compli-
cated as the field of cellular therapy itself. The variety of
tissue sources of stem cells (embryonic, adult bone marrow,
umbilical cord, placenta, adipose tissue, etc.); autologous
versus allogeneic donation; types of cells (hematopoietic,
mesenchymal stromal, progenitor, and mixed populations);
confusion and stigmatism by the public and patients regard-
ing gene, protein, and stem cell therapy; scaling of manu-
facturing; and the changing regulatory environment all
contribute to the small number of Phase 3 trials and lack
of approvals.
This review article provides an overview of the progres-
sion of research from gene therapy to the cellular therapy
field as it applies to peripheral arterial disease, as well as the
position of Aastrom’s cellular therapy, ixmyelocel-T, within
this field.
Historical Perspective of the Overlap Between Gene
and Cell Therapies
Pioneering work by Folkman in the 1970s led to develop-
ment and eventual approval of anti-angiogenic treatments
for cancer [2]. The discovery of angiogenic growth factors
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and signaling molecules that initiate and promote growth
and survival of new blood vessels [3] captured the attention
of cardiovascular investigators, who began testing the
effects of growth factor stimulation on perfusion and func-
tion of ischemic tissues, independent of macrovessel sur-
gery. Within the same timeframe, pioneering work was
accomplished by British [4] and American scientists [5] in
the isolation and culture of pluripotent embryonic stem cells
(ESCs) from the inner cell mass of pre-embryos. During the
1980s and 1990s, stem cell research exploded; however,
controversy over human cloning and embryo destruction
led to policies that restricted ESC research. Only three Phase
1 clinical trials using ESCs have been conducted since 2010
[6]; the 3 studies were for indications of macular dystrophy,
macular degeneration, and spinal cord injury.
Clinical research conducted using stem cells and stem
cell-derived therapy from sources considered to be non-
controversial have included research of adult multipotent
stem cells from bone marrow, adipose tissue, umbilical cord,
placenta, and endometrial tissue. Diseases studied have in-
cluded graft versus host, Crohn’s, osteogenesis imperfecta,
Parkinson’s, Alzheimer’s, and diseases of the cardiovascular
system such as myocardial infarction, heart failure, and
peripheral arterial disease (PAD).
Pathophysiology of Severe Peripheral Arterial Disease
Severe PAD, or critical (limb-threatening) limb ischemia
(CLI), occurs when arterial blood flow is restricted to such
an extent that the nutritive requirements of tissue can’t be
met [7]. Ordinarily, compensatory mechanisms, including
capillary sprouting as well as arteriogenesis [8], alleviate the
effects of the deprivation, but in patients with CLI these
mechanisms are exhausted. Inadequate blood flow to the
skin and surrounding tissues leads to endothelial dysfunc-
tion, chronic inflammation [7], and muscle damage [9, 10].
The net effect of these changes is the occurrence of rest pain,
chronic non-healing wounds, and gangrene. Treatment of
severe PAD usually involves an attempt to address restricted
blood flow through lower extremity revascularization using
open bypass surgery or endovascular percutaneous interven-
tion. While patients have benefits like wound healing from
restoration of blood flow, simply reinstating flow on a
macrovascular level does not reverse the damage of the
alteration of structure and function of the endothelium and
surrounding tissues that has occurred with severe PAD [8].
Limitations of the surgical or endovascular approach
includes the increased mortality risk with open bypass pro-
cedures, restenosis, re-occlusion, re-intervention, and con-
tinued pain and expense of extensive wound care [11–13].
In addition, approximately 40 % of patients are not eligible
for revascularization [14], leaving an opening for filling an
unmet medical need in these very ill patients. The 5-year
mortality rate for the most severe form of PAD is 60 % [15],
exceeding that of prostate cancer (<1 %) [16], breast cancer
(11 %) [17], acute myocardial infarction (20 %) [18], colo-
rectal cancer (36 %) [19], and stroke (41 %) [20]. Cellular
therapies may provide a treatment solution that has the
potential to address multiple aspects of severe PAD including
reduction of inflammation, tissue remodeling, and increased
perfusion.
The sections below provide a summary of the preclinical
evidence and the results of clinical trials in severe PAD for
each of the gene and cellular therapy types. Table 1 provides
a summary of ongoing or completed Phase 3 clinical trials
by gene or cellular therapy type, Phase 2 clinical trials
ongoing or completed and reported in the literature, and
unique ongoing pilot studies.
Gene Therapy
Angiogenic Growth and Transcription Factors
The biological process for wound repair is initiated immedi-
ately after injury by release of various growth factors and
cytokines. Therefore, angiogenic growth factors have been
likely candidates for biological therapy and have been studied
for the treatment of ischemic disease. Isner et al. published the
first preclinical studies of therapeutic angiogenesis in the
treatment of limb ischemia in 1995 [21, 22]. Several growth
and transcription factors have advanced from basic research
into vascular clinical trials for the treatment of PAD. These
include vascular endothelial growth factor (VEGF), hepatocyte
growth factor (HGF), hypoxia inducible factor-1α (HIF-1α),
fibroblast growth factor (FGF), and stromal-derived factor
(SDF-1). There is extensive preclinical research showing the
angiogenic potential for each of these factors.
The VEGF family, comprised of seven major isoforms, is
the most widely studied endothelial growth factor [23].
VEGF, a key promoter of angiogenesis, stimulates prolifer-
ation, migration, and vascular formation and mobilizes en-
dothelial progenitor cells [24–28]. The therapeutic potential
of VEGF has been shown in PAD models where bolus
injection of VEGF increased blood perfusion and tissue
oxygenation [29–31]. Clinical trials using various isoforms
were primarily conducted during the early 2000s (Table 1).
Only one of the placebo-controlled trials had a positive
primary endpoint of vascularity as measured by digital
subtraction angiography, but all secondary outcomes were
negative relative to placebo [32]; all other trials were nega-
tive for the primary efficacy measures [23]. In addition, one
of the clinical trials demonstrated dose-dependent peripheral
edema in patients receiving VEGF [33].
FGF, consisting of 23 structurally related proteins, is a
regulator of angiogenesis through potent mediation of
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Table 1 Clinical trials by gene or cellular therapy type
Sponsor/cell type Phase/NCTa/Status/Design Primary Efficacy Outcomes/
Scientific Publications
Sponsors with PHASE 3 Studies







Phase 2/Completed Time to first occurrence of treatment failure (TTF) was significantly longer for
patients treated with ixmyelocel-T compared to control patients (p=0.0032,
logrank test). TTF was defined as the earliest trial day on which any of the
following treatment failure events occurred: major amputation of the injected
leg, all-cause mortality (death), doubling of total wound surface area from
baseline, and de novo gangrene. The survival curves diverged early and the
difference between groups was maintained throughout the 12-month follow-up
period. The Cox PH analysis gave a treatment HR=0.381, 95 % CI=(0.195,
0.744), conveying a significant reduction in the risk of treatment failure in the
ixmyelocel-T treatment group of approximately 62 % (p=0.0047). The
individual components of the treatment failure composite endpoint all trended
in the same direction, favoring ixmyelocel-T treatment, with the exception of





Harvest Technologies Phase 3/Active recruiting AFS at 6 months
NCT01245335
210 patients
(Device) Randomized, DB, PBO-
controlledBM-MNC; autologous
Phase 2/Ongoing Time to amputation was longer in the BMAC group than in the placebo group
(p=0.067). In patients with tissue loss, treatment with BMAC demonstrated
a lower amputation rate than placebo (39.1 % vs 71.4 %; p=0.1337).
Wound healing was not reported. Change in Rutherford Class (patients who
improved at least one numeric category) showed that in Rutherford 4
patients, 81.8 % of the BMAC patients improved while 42.9 % of control
patients improved (p=0.0874); there was only a small difference in improve-







TAMARIS provided no evidence that NV1FGF is effective in reduction of
amputation or death in patients with CLI [37].




NV1FGF Similar rates of ulcer healing occurred with NV1FGF (19.6 %) and PBO
(14.3 %; P=0.514). The use of NV1FGF reduced by 2-fold the risk of
all amputations [HR 0.498; P=0.015] and major amputations (HR 0.371;
P=0.015) in the MITT study population (18 patients were excluded from
efficacy analyses; the robustness of findings in relation to the occurrence
of amputation, death, and AFS was confirmed in the total randomized
population; however data were not shown). There was no statistically








Sponsors or Investigators with PHASE 2 Studies
Makinen, 2002 Phase 2/Completed Positive vascularity; negative restenosis rate, Rutherford class, and ABI [32]
VEGF-165 54 patients
(adnovirus/plasmid) DB, randomized, PBO-
controlled
RAVE Phase 2/Completed Negative for peak walking time, ABI, claudication onset time, and Quality of
life. Treated arm associated with dose-dependent peripheral edema [33]Rajagopalan, 2003 105 patients
VEGF-121 (adenovirus) DB, randomized, PBO-
controlled
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Table 1 (continued)
Sponsor/cell type Phase/NCTa/Status/Design Primary Efficacy Outcomes/
Scientific Publications
GRONINGEN Phase 2/Completed Negative for amputation rates; improvement in ulcer healing and ABI [98]
Kusumanto, 2006
VEGF-165 (plasmid) 54 diabetic patients
DB, randomized, PBO-
controlled
Viromed Co, Ltd Phase 2/Active recruiting Difference in pain level between baseline and 9 month follow-up as
determined by VASNCT01064440
Growth factor HGF (2
isoforms HGF




AnGes Phase 2/Completed Change in TBI significantly improved from baseline at 6 months in the HGF-
treated group compared with placebo (0.05±0.05 vs -0.17±0.04; P=0.047).
Change in VAS from baseline at 6 months was also significantly improved
in the HGF-treated group compared with placebo. Complete ulcer healing
at 12 months occurred in 31 % of the HGF group and 0 % of placebo
(P=0.04). There was no difference in major amputation of the treated limb
(HGF 29 % vs placebo 33 %) or mortality at 12 months (HGF 19 % vs
placebo 17 %) [43].






TcPO2 (mean SE) increased at 6 months in the high-dose group (24.0_4.2 mm
Hg, 95 % CI 15.5 to 32.4 mmHg) compared with the placebo (9.4_4.2 mm
Hg, 95 % CI 0.9 to 17.8), low-dose (11.1_3.7 mmHg, CI 3.7 to 18.7 mmHg),
and middle-dose (7.3_4.8 mmHg, CI _2.2 to 17.0 mmHg) groups (ANCOVA
P_0.0015). There was no difference between groups in secondary end points,
including ankle brachial index, toe brachial index, pain relief, wound healing,





Genzyme Ad2/HIF-1α/VP16 No significant differences in claudication onset time, ABI, or quality of life
measurements between placebo and each of 4 HIF-1α dose groups [99]WALK study NCT00117650





Juventas Therapeutics, Inc SDF1 Tracking of major/minor amputations, overall survival, QoL, ulcer healing, and
pressure assessmentsPhase 2/Active recruiting




UMC Utrecht for BM-MNC
study
48 patients
BM-MNC autologous Major amputation (primary), number and extent of leg ulcers, resolution of





TACT study group Pilot study and Phase 2a At 4 weeks, ABI was significantly improved in legs injected with BM-MNC
compared to PB-MNC. Similar improvements were seen for transcutaneous
oxygen pressure and pain free walking time. These improvements were
sustained at 24 weeks [101]
BM-MNC and PB-MNC NCT00145262
25 patients with unilateral
disease in pilot study who
were injected with BM-
MNC, followed by 22
patients with bilateral
disease who were randomly
injected with BM-MNC in
one leg and PB-MNC
in the other leg as control.
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endothelial cell migration, differentiation, and survival [34].
Ashara et al. was the first to show that FGF improved
perfusion in an animal model of ischemia [35]. The results
of 2 clinical trials have been published: a Phase 2 and a
Phase 3 trial were completed using injections of NV1FGF,
nonviral naked FGF plasmid DNA. Both studies were
placebo-controlled. In the Phase 2 study there was a signif-
icant difference favoring NV1FGF treatment in the
Table 1 (continued)





Phase 1–2/Completed Intra-arterial administration of BM-MNC did not significantly increase ABI.
Cell therapy was associated with significantly improved ulcer healing
versus placebo, and reduced rest pain versus placebo within 3 months.
Limb salvage and amputation-free survival rates did not differ between the
groups [102]
NCT00282646
BM-MNC; autologous 40 patients
DB, randomized, PBO-
controlled
Losordo, Douglas, M.D. Phase 1–2/Completed A single administration of unmodified, autologous CD34 cell therapy was
associated with significantly reduced rates of amputation in subjects with
Rutherford class 4 and 5 critical limb ischemia. Ongoing analysis will
examine additional endpoints, and will determine sample size and








Biomet Biologics, LLC Phase not stated/Active
recruiting





BM-MNC Phase 1–2/Completed AFS at 1 year was 86.3 %. There was a significant increase in FTP and TBI,
and a trend in improvement in ABI. The VascuQol questionnaire
demonstrated significant improvement in quality of life, and 3 of 9 ulcers
(33 %) healed completely [104]








G-CSF mobilized PB-MNC 60 patients
Randomized, DB,
PBO-controlled
Pluristem, Ltd Phase 2/Not yet recruiting Primary outcome: Log ratio of week 52 maximal walking distance(MWD) to




Medistem, Inc. (Device) Phase 1–2/Not yet recruiting
in US
Improvements post-treatment in rest pain (VAS), toe pressure and ABI,






Initiated in China (2 patients
treated in early July 2012)
Investigator Trial
(Northwestern University)
Phase 1/Active recruiting ABI (15 % will be considered improvement), healing of ischemic ulcers, and
decreased pain-follow-up at 1, 6, 12, and 24 monthsNCT01019681
Cord Blood injection IM 25 patients
OL, nonrandomized
a NCT (National Clinical Trial Number) if available
ABI ankle brachial index, DB double-blind, PBO placebo
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secondary endpoint of amputation-free survival (AFS);
however, none of the other endpoints were supportive of
this finding including wound healing, rest pain, or death
[36]. The large Phase 3 study conducted with 525 patients
was negative for all endpoints (Table 1) [37].
HGF is a cytokine known to regulate cell growth, motil-
ity, morphogenesis and angiogenesis through activation of
tyrosine kinase [38, 39]. In preclinical models, HGF has
been shown to induce robust collateral formation [40, 41].
Expression of HGF was found to be strongly upregulated in
cells of the wound epidermis during healing of excisional
wounds in rats [42]. Two placebo-controlled clinical studies
were conducted evaluating treatment of CLI patients with
HGF. In the first study of 27 patients, change in toe brachial
index was significantly improved from baseline at 6 months
of follow-up in the HGF-treated group compared with pla-
cebo, and there was complete ulcer healing at 12 months in
31 % of HGF-treated compared to 0 % of placebo patients
[43]. In the second study conducted by the same investiga-
tional group, 106 CLI patients were randomized to placebo
(N=26) or to 1 of 4 doses of HGF (N=78). In all evaluable
groups, measurement of blood flow by transcutaneous oxygen
tension (TcPO2) at 6 months increased from baseline in HGF-
treated relative to placebo patients; the highest increase was in
the high-dose HGF group. All other endpoints were negative
[44]. A Phase 3 study is planned to begin in 2012 in 560 CLI
patients with rest pain or tissue loss [45].
HIF-1α, a transcription factor, regulates oxygen homeo-
stasis and metabolism through adaptive responses to hypoxia
at the cellular level [46–51], coordinating effort on multiple
pathways that regulate angiogenesis, including VEGF, as well
as pathways relevant to cell survival and metabolism [52–55].
In preclinical studies using rabbit hindlimb ischemia,
administration of HIF-1α increased collateral blood vessels,
capillary density and regional blood flow [56], and in a murine
diabetic model of CLI enhanced neovascularization, mo-
bilized progenitors cells from the bone marrow, and
improved tissue perfusion [57]. Only one Phase 2 HIF-
1α trial in patients with PAD has published results at the time
of this manuscript (see Table 1; NCT00117650); in this trial
HIF-1α was not shown to be an effective treatment for
patients with intermittent claudication, a less severe form of
PAD than CLI.
SDF-1 is a chemokine that is rapidly overexpressed in
response to tissue injury. In the ischemic mouse hind limb,
SDF-1 was shown to enhance angiogenesis [58]. SDF-1 has
unique properties compared with the effects of angiogenic
growth factors, including the absence of significant mito-
genic actions which may prevent uncontrolled endothelial
cell proliferation and subsequent formation of enlarged tor-
tuous vessels, common in VEGF-induced angiogenesis
[59]. Rapid inactivation of the chemokine in the protease-
rich environment of the ischemic limb was addressed in the
design by Segers et al. of recombinant SDF-1 proteins carrying
mutations that provide resistance to protease cleavage [60].
Only one clinical trial is currently being conducted exploring
the therapy value of SDF-1 (Table 1). The study is a Phase 2
trial that is currently ongoing.
Cellular Therapies
Mononuclear Cell Fraction/Endothelial Progenitor Cells
The exploration of both autologous bone marrow (BM) and
peripheral blood (PB) mononuclear cells (MNCs) for the
treatment of ischemic disease has been explored for more
than 10 years. These mononuclear cells, also called endo-
thelial progenitor cells (EPC), are obtained from the CD34+
stem cell fraction of adult bone marrow and peripheral blood
through cell separation techniques, and have the same line-
age as hematopoietic stem cells with several shared surface
antigens including KDR, Tie-2/Tek, and CD34 [61]. Early
evidence showed postnatal neovascularization activities in
response to ischemia including response of resident endo-
thelial cells, but also the proliferation, differentiation, mi-
gration, and incorporation of BM-derived EPCs [62–65]. It
was shown in experiments that EPCs specifically home to
sites of ischemia and incorporate into capillaries and inter-
stitial arteries in models of limb and myocardial ischemia
[63, 66, 67]. EPCs have been shown in preclinical studies to
improve capillary density in hindlimb models of ischemia
[61, 68]. A review of the clinical study literature by
Sprengers in 2008 found 25 published reports of clinical
studies of BM-MNCs or PB-MNCs [69]. Most of the studies
were case or patient series, 1 was a pilot, and 2 were
randomized clinical trials. Results from the 2 randomized
trials are presented in Table 1. In a review of stem and
progenitor cell therapy by Lawall [70], the author concluded
that despite the limitations of published BM-MNC clinical
studies (small number of patients, lack of control group, and
differing primary efficacy measurements), the outcomes
were remarkably consistent. Clinical course (wound
healing, walking distance) and perfusion parameters (ankle
brachial index [ABI], TcPO2) were consistent and positive
across trials. There are 2 studies using BM-MNC therapy
actively recruiting patients (Table 1).
Mesenchymal Stromal Cells
Mesenchymal stromal cells (MSCs) were first identified in
bone marrow 40 years ago [71]. MSCs are plastic-adherent
cells that were shown to differentiate into osteoblasts, adi-
pocytes, and chondrocytes in the 1980s [72, 73]. Caplan et
al. showed that surrounding conditions are critical for in-
ducing MSC differentiation [73]. In the 1990s, Pittenger et
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al. demonstrated that individual adult human MSCs were
capable of expanding to colonies while still retaining their
multipotency [74]. An essential characteristic of MSCs is
that they home to damaged tissues and have been shown to
regulate immune and inflammatory responses at target sites
[75–79]. Isolation of MSCs have been performed in tissues
other than bone marrow, including peripheral blood [80],
cord blood [81], adipose tissue [82], synovial membrane
[83], and placenta tissue [84]. Baksh et al. showed that
MSCs derived from different tissues show phenotype
heterogeneity and different growth abilities but also show
similarities, with the potential to differentiate into the classical
mesenchymal lineages [85]. There are a broad number of
indications under study for treatment with MSCs; at the time
of this article there were 254 active clinical trials for MSCs
listed on clinicaltrials.gov. Some of the studies use allogeneic
sources of cells and some use autologous. Indications include
graft versus host disease, heart failure, diabetes, Parkinson’s,
arthritis, aplastic anemia, Crohn’s disease, and multiple
sclerosis. Of the 254 studies, 13 are listed with an indi-
cation of CLI and 1 with an indication of intermittent
claudication (IC). Almost all of these studies are being
conducted outside of the United States (U.S.), primarily in
India and China; only the IC study has sites listed for
recruitment in the U.S. There are no published results in
peer-reviewed journals for early clinical trials using MSC-
only therapy for the treatment of PAD.
Mixed Cellular Therapy
One hypothesis is that a mixture of regenerative cell types
like MSCs (CD90+) and alternatively activated or M2 mac-
rophages (CD14+ that express CD206+ and/or CD163+),
rather than a single cell type, may be required to promote
long-term tissue regeneration and repair [86, 87]. Aastrom
Biosciences, Inc. manufactures ixmyelocel-T, an autologous
multicellular therapy expanded from a patient’s own bone
marrow. Ixmyelocel-T is composed of a mixture of cell
types that include those expected to be found in the BM-
MNC population. These include myeloid cells (granulo-
cytes, monocytes, and mixed myeloid progenitors) and lym-
phoid cells (T cells, B cells, and mixed lymphoid
progenitors) that express CD45 on the cell surface, and
CD90+ MSCs/stromal cells, and CD45+CD14+ autofluores-
cent+ (CD14+Auto+) macrophages. While the cell types are
similar to those found in the BM-MNC population, the
numbers of CD90+ and CD14+Auto+ cells are significantly
greater in ixmyelocel-T due to expansion during the manu-
facturing process. The manufacturing process and cell char-
acterization of the product have been described previously
[88, 89]. In in vitro studies it has been demonstrated that
ixmyelocel-T produces anti-inflammatory cytokines which
may aid in the healing process [90]. A Phase 2b clinical
study (RESTORE-CLI) was successfully completed in 2011
[91], with results presented at the American Heart Associa-
tion Scientific Sessions 2011 [92]. RESTORE-CLI was not
powered to show statistical significance for efficacy end-
points; despite that limitation; however, there was a statisti-
cally significant difference in the time to first occurrence of
treatment failure. The treatment failure composite, which
consisted of major amputation of the index leg, all-cause
mortality, doubling of wound total surface area from base-
line and de novo gangrene can be considered a Phase 2
surrogate for the Phase 3 AFS (major amputation of the
index leg, all-cause mortality) endpoint since tissue loss
and gangrene are associated with higher rates of amputation
and lower rates of survival [93]. Time to first occurrence of
treatment failure is the earliest day at which any of the
treatment failure events occurred. There was a 62 % risk
reduction in treatment failure over the 12-month follow-
up in the ixmyelocel-T group compared to the control
group (hazard ratio 0.38, 95 % confidence interval=0.20
to 0.74). The individual components of the treatment
failure composite endpoint all trended in the same direc-
tion, favoring ixmyelocel-T treatment, with the exception
of all-cause mortality that was the same in both treatment
groups. A pivotal Phase 3 clinical trial (REVIVE) is
being conducted under a Special Protocol Assessment
(SPA) approved by the FDA, and began screening
patients in 2012.
Discussion
There is a large body of preclinical research demonstrating
the efficacy of gene and cellular therapy in peripheral arte-
rial disease including evidence for growth and transcription
factors, monocytes, and mesenchymal stem cells. However,
thus far, clinical investigations have remained trapped in
earlier phase studies, with the exception of fibroblast growth
factor which advanced to a large-scale Phase 3 clinical trial.
The disappointing results of this trial as well as the mixed
positive and negative results from early clinical trials in both
gene and cellular therapy, the complexity of the stem cell
field, and the changing regulatory landscape have contrib-
uted to both the perception and the reality of the slow
progression of research into later phase clinical trials.
Among the complicating factors are differing composition
and biologic activities within the field of candidate therapies
in the gene and stem cell fields. Gene therapy, the delivery of a
single gene to the ischemic tissue of interest, requires expres-
sion of resident cells at the right time and place for efficacy
[94]. Promotion of a single gene expression may not address
the complexity of the underlying disease. Cellular therapies
with adult stem cells have either autologous or allogeneic
sources of cells, as well as differences in cell types. Allogeneic
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sources generally involve a single cell type such as MSCs.
The expansion of the cells in vitro is essential for cost effec-
tiveness and ‘off the shelf’ use. However, in vitro expansion
may decrease the efficacy of the cells, causing dose to be an
issue as well as engraftment potential of the cells. Repeat or
multiple dosing may elicit an immune response. The require-
ments for follow-up of side effects and hurdles of regulatory
oversight are more extensive for therapies using allogeneic
cell sources. Autologous cell therapy can harvest single or
multiple cell types. Using the patient’s own cells has advan-
tages for safety, the maintenance of potency, and the potential
for long-term engraftment and clinical effects. Multiple cell
types have the potential to deliver multiple mechanisms to
address complex diseases. Autologous cell products have
more complex manufacturing and logistical issues, but there
is the advantage of strict quality control for manufactured
products over point of care devices. Autologous cell therapy
developed using bedside devices that concentrate a larger
volume bone marrow aspirate for reinjection to ischemic
tissue are not as strictly quality controlled, but as devices have
lower regulatory hurdles compared with manufactured
autologous cell therapies.
The traditional drug development pathway of pharmaco-
kinetic and preclinical modeling does not always translate
well for stem cell products. As a result, much of the tradi-
tional ‘preclinical’ work must be done and will continue to
be done within the framework of clinical trials, while still
demonstrating proof of concept with in vitro studies and
applicable in vivo models. Therefore, it is vitally important
to communicate and use standardized protocols for the
evaluation of efficacy and safety in both preclinical and
clinical evaluation of cellular products. Early clinical trials
used measurements of blood flow as the primary efficacy
measure (e.g., ABI or TcPO2); however, there is poor cor-
relation between leg blood flow and functional disability in
patients with PAD [95]. The influence of the requirement by
FDA to use AFS as the primary efficacy measurement in
later phase clinical trials for severe PAD is reflected in the
primary efficacy measures listed on clinicaltrials.gov for
device trials as well as trials being conducted outside the
U.S.
The past 15 years of clinical trials in gene and cell therapy
for PAD have provided important knowledge and insights in
regenerative medicine for vascular disease. There has been
critical movement towards standardized, quality controlled,
good manufacturing processes and protocols for the isolation
and reintroduction of cells [6]. There are currently only two
Phase 3 trials currently recruiting patients for the treatment of
severe PAD with sites in the U.S. [96], including Aastrom’s
trial with ixmyelocel-T, a multicellular expanded product, and
a Harvest Technologies device trial using bedside concentra-
tion of BM-MNCs. Both of these trials use autologous bone
marrow as the source of cells. In addition, a Phase 3 study is
being planned for the evaluation of HGF [45]. The completion
of these studies will add to the base of knowledge and provide
new pieces of the regenerative medicine puzzle. Studies using
allogeneic sources, including placental, cord blood, and endo-
metrial tissue, remain in early-phase development.
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